The Foundation's focused strategy includes funding and actively monitoring the progress of scientific research projects in key pathways towards a cure, providing financial and logistical support to promising drug candidates to accelerate them to clinical trials, funding clinical trials and studies, encouraging collaboration among scientists, and educating LGMD2B/Miyoshi patients about their disease and helping them with their diagnosis (e.g., funding dysferlin protein and gene mutational analysis).
About the Sponsors
Coalition to Cure Calpain 3 (C3) was founded in 2010 for the specific purpose of funding research efforts focused on understanding the biology of and finding a cure for LGMD2A/Calpainopathy. This organization was created by people with LGMD2A for people with LGMD2A, as both founders have this progressive disease. We are motivated by our desire to encourage collaboration among scientists, those who have LGMD2A, their families, friends and the community-at-large to bring an end to this under-researched, underfunded "orphan" disease.
The Jain Foundation is a non-profit foundation whose mission is to cure muscular dystrophies caused by dysferlin protein deficiency, which includes the clinical presentations Limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi muscular dystrophy 1 (MMD1). The foundation is privately funded and does not solicit funding from patients or other sources.
The LGMD2D Foundation is a non-profit private foundation whose mission is to expedite the development of a cure or therapy for Limb-Girdle Muscular Dystrophy 2D (LGMD2D). In addition to educating patients and physicians, the Foundation maintains a patient registry, funds and monitors research and progress, provides financial support to accelerate clinical trials, and encourages scientific collaboration.
The LGMD2I Research Fund is a not-for-profit focused on expediting the development of a treatment or cure for Limb Girdle Muscular Dystrophy 2I (LGMD2I). We do that by building a comprehensive view of the entire LGMD2I research landscape, supporting the most promising research projects, and coordinating and managing the scientific process. More information at www.lgmd2ifund.org.
The Kurt+Peter Foundation was formed by the family and friends of Kurt and Peter Frewing to raise money and direct it into the hands of researchers who have the best shot at developing a treatment or cure for LGMD2C. Since 2010, the Kurt+Peter Foundation has raised more than $1 million for research into LGMD2C. Among other initiatives, the foundation is currently funding development of an exon skipping compound that the foundation hopes will treat the majority of LGMD2C mutations.
The McColl-Lockwood Laboratory for Muscular Dystrophy Research was created to develop experimental therapies for the treatment of the muscular dystrophies and to facilitate the translation of these therapies to clinical trials for improving the quality of life for patients with the disease. The McColl-Lockwood Laboratory for Muscular Dystrophy Research focuses on developing novel therapies for muscular dystrophy, specifically limb-girdle muscular dystrophy (LGMD). The McColl-Lockwood Laboratory is funded with the support from the Carolinas Muscular Dystrophy Research Endowment, which was created by the McColl and Lockwood families, additional funding is from the Carolinas HealthCare Foundation as well as federally funded grants. Significant progress made by the McColl-Lockwood Laboratory in the last few years is the result of effective collaborations between many world renowned laboratories with research focuses on muscular dystrophies speed up the progress in searching for effective therapeutics for muscular dystrophies. The institutes include, but are not limited to the following: Children's National Medical Center, Washington DC; University of North Carolina, Chapel Hill; University of Iowa; University of Oxford UK; Cardiff University, UK; National Institute of Neuroscience, Tokyo, Japan.
The Cecil B. Day Family has been supporting muscular dystrophy research since 1984 and have family members affected by LGMD2B/Miyoshi Myopathy. Their funding was instrumental in the identification of the dysferlin gene as the cause of LGMD2B/Miyoshi, which has allowed researchers to better understand the disease and begin working towards developing treatments.